subscribe
 

Webinar addresses 3D cell-based models for regenerative medicine

Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for...

Propofol discovery may help lead to development of new anaesthetics

New research on the most commonly used anaesthetic drug could help to unravel a long-standing mystery about how it induces a pain-free, sleep-like state.

Toolkit for nucleosome & histone research

AMSBIO has announced addition of new biotinylated histones and nucleosomes to its expanding range of recombinant nucleosomes, purified...

Presenting phenotypic screening strategies for chronic pain research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, invites researchers to join the webinar...

University launches search for ‘returning’ scientists

The University of York has launched an initiative to attract more scientists, who have taken a career break, back into the world of...

Polyphor achieves first milestone in macrocycle drug discovery collaboration with Boehringer Ingelheim

Polyphor, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, has announced that Boehringer Ingelheim has decided to enter into the next stage of its drug discovery collaboration with...

Men with incurable prostate cancer living for twice as long as decade ago

Patients with advanced prostate cancer treated with the latest therapies are living on average for more than twice as long as a decade ago, a striking new analysis reveals.

Novartis receives positive CHMP opinion for Ilaris®

Novartis receives positive CHMP opinion for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis.

Cheaper anti-cancer drug as effective as expensive drug in treating most common cause of blindness in older adults

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.

Roche launches new ProGRP test for more precise diagnosis in lung cancer

New test expands cancer diagnostics portfolio and strengthens Roche Diagnostics’ comprehensive tumour marker menu.

Galen acquires Synera® (lidocaine 70mg/tetracaine 70mg) topical patch

Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma Inc., a wholly owned subsidiary of Nuvo Research Inc.

Roche halts investigation of aleglitazar

Roche has announced that following the results of a regular safety review of the aleglitazar AleCardio phase III trial, the independent Data and Safety Monitoring Board (DSMB) has recommended to halt the trial due to safety signals and lack...

Technological breakthrough paves the way for better drugs

Researchers at Karolinska Institutet in Sweden have developed the first method for directly measuring the extent to which drugs reach their targets in the cell.

Staphylococcus aureus vaccine

A consortium comprising Imaxio, the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.

Victrix CMCC chooses Cresset’s software for drug discovery consulting projects

Under a new agreement, Victrix CMCC will use Cresset’s software for their computational chemistry consulting projects.

3D spheroid assays for cancer drug screening

AMSBIO has introduced a new range of 96-well format 3D Spheroid Cell Proliferation / Viability Assays, providing a new tool to allow...

Clot-buster trial reveals long-term benefits for stroke patients

Patients given a clot-busting drug within six hours of a stroke are more likely to have a long-lasting recovery than those who do not receive the treatment, new research has found.

Public to see impact of medical research funding

Europe’s largest store of open-access biomedical literature has joined forces with a leading online research outcomes system to connect research articles and grants with data on their impact.

‘Next generation’ cancer drug shows promise in early trial

A new potential cancer drug has shown promising results in an early stage clinical trial. The drug, called AUY922, could help lead to a new way to treat a wide range of cancers including breast and lung cancer.

Cobra Biologics and Novolytics unveil successful development of bacteriophages against bacterial infection

Cobra Biologics and Novolytics have announced a breakthrough in the development of two Staphylococcus aureus based phage products for Phase I clinical trials with a 100 fold increase in upstream process yields.

Pages

Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe